EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Systematic Characterization of AML Cell Lines to Support Preclinical In Vitro CAR-T Research

Vassa D Davydova iD, Anastasia A Zotova, Nikolay M Kapranov, Dmitry V Dianov iD, Yulia O Davydova, Tatiana A Nenasheva iD, Irina Y Zaichenko iD, Sergei D Losev iD, Kseniia A Nikiforova, Irina V Galtseva, Apollinariya V Bogolyubova iD

Cells · 28.10.2026 · 15 (21) · 1964

DOI: 10.3390/cells15211964 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 28.10.2026. Verfasst von Vassa D Davydova und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Precision Genetic Technologies for Medicine, National Medical Research Center for Hematology, Moscow 125167, Russia. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Ministry of Science and Higher Education of the Russian Federation, Ministry of Science and Higher Education of the Russian Federation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of chimeric antigen receptor (CAR) T cell therapies for acute myeloid leukemia (AML) remains challenging, underscoring the need for reliable preclinical models. Although AML cell lines are widely used in CAR-T studies, their ability to reflect clinically relevant antigen expression patterns and functional characteristics of primary AML cells has not been systematically evaluated. We characterized nine AML cell lines (KG-1, HL-60, Kasumi-1, OCI-AML2, OCI-AML5, THP-1, U-937, MV4-11, and MOLM-13) as targets for in vitro CAR-T studies. We assessed the expression of established CAR-T target antigens (e.g., CLL1, CD33), cell lines similarity to minimal residual disease (MRD) cells and matched healthy monocytes from 161 AML patients, the expression of emerging AML-associated antigens (Siglec-6, CSF1R, and CD70), growth behavior, and susceptibility to non-specific killing by non-transduced T cells. AML cell lines demonstrated substantial heterogeneity in antigen expression with several cell lines showing antigen densities exceeding those observed in AML blasts. Several widely used lines, including U-937, were susceptible to non-transduced T-cell cytotoxicity, potentially confounding CAR-T functional assays and overestimating CAR-T activity in vitro. The examined parameters were integrated into a scoring framework to rank AML cell lines according to their suitability for in vitro CAR-T studies. Based on this framework and additional assay-related considerations, OCI-AML2, OCI-AML5, MV4-11, and MOLM-13 were identified as most suitable for in vitro evaluation of CAR-T products, particularly those targeting CD33 and CLL1. These findings may facilitate more informed selection of AML cell lines for preclinical development of CAR-T therapies for AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteReceptors, Chimeric AntigenImmunotherapy, AdoptiveHumansCell Line, TumorT-LymphocytesFemaleMaleAdultAgedMiddle Aged

Stichwörter der Autor:innen

AML cell lineacute myeloid leukemiachimeric antigen receptorco-culturecytotoxicityin vitro CAR-T study

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Center for Precision Genetic Technologies for Medicine, National Medical Research Center for Hematology, Moscow 125167, Russia.
  • National Medical Research Center for Hematology, Moscow 125167, Russia.

ORCID-Profile: Vassa D Davydova, Dmitry V Dianov, Tatiana A Nenasheva, Irina Y Zaichenko, Sergei D Losev, Apollinariya V Bogolyubova

Förderung

  • the Ministry of Science and Higher Education of the Russian Federation
  • Ministry of Science and Higher Education of the Russian Federation

Zitieren

APA

Davydova, V. D., Zotova, A. A., Kapranov, N. M., Dianov, D. V., Davydova, Y. O., Nenasheva, T. A., Zaichenko, I. Y., Losev, S. D., Nikiforova, K. A., Galtseva, I. V., & Bogolyubova, A. V. (2026). Systematic Characterization of AML Cell Lines to Support Preclinical In Vitro CAR-T Research. Cells, 15(21), 1964. https://doi.org/10.3390/cells15211964

Vancouver

Davydova VD, Zotova AA, Kapranov NM, Dianov DV, Davydova YO, Nenasheva TA, et al. Systematic Characterization of AML Cell Lines to Support Preclinical In Vitro CAR-T Research. Cells. 2026;15(21):1964. doi:10.3390/cells15211964

BibTeX
@article{Davydova2026,
  author = {Davydova, Vassa D and Zotova, Anastasia A and Kapranov, Nikolay M and Dianov, Dmitry V and Davydova, Yulia O and Nenasheva, Tatiana A and Zaichenko, Irina Y and Losev, Sergei D and Nikiforova, Kseniia A and Galtseva, Irina V and Bogolyubova, Apollinariya V},
  title = {Systematic Characterization of AML Cell Lines to Support Preclinical In Vitro CAR-T Research},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {21},
  pages = {1964},
  doi = {10.3390/cells15211964}
}
Kostenlos starten →